Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 19, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD)...
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 20, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy...
Celldex Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: ...
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU...
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024 17:43 ET
|
Celldex Therapeutics, Inc.
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into...
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 25, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in two of...
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024 10:45 ET
|
Celldex Therapeutics, Inc.
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust...
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company’s Phase 2 clinical trial of...
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: 2024...
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be...